FGFR, or fibroblast growth factor receptor, plays a role in cell division and maturation. About one in five people with recurrent or refractory bladder cancer has genetic mutations in the genes that ...

Patients with Stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery. 87% of patients remained alive and 80% were disease free four years after treatment.

People treated with the targeted therapy had superior response rates and experienced fewer side effects than those who used older TKI drugs, but these benefits come at a higher cost.

Miracle Mineral Solution and other products containing sodium chlorite—an oxidizer chemically similar to household bleach—can cause severe vomiting and diarrhea and is not effective as a treatment for ...

“In many countries, chemotherapy is still the optimal treatment option for these patients, who have an overall survival of less than a year,” Ji said. “There is a great unmet medical need to explore ...

The Food and Drug Administration (FDA) has approved the PI3K inhibitor Piqray (alpelisib) in combination with Faslodex (fulvestrant) for postmenopausal women, and men, with previously treated hormone ...

Researchers report good 10-year survival for people with melanoma and improvements for those with triple-negative breast cancer and bladder cancer.

Prior to becoming the Democratic vice-presidential candidate, Kamala Harris expressed her strong support for better health care for all Americans. She credits much of her passion on this issue to her ...

NIH-funded researchers led by Dr. A. Eden Evins at Massachusetts General Hospital wanted to know if an FDA-approved smoking cessation drug called varenicline could help youth quit nicotine vaping. The ...

Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common ...

To create a customized cancer vaccine, scientists genetically sequence a patient’s tumor and identify neoantigens—abnormal proteins unique to cancer cells—that are most likely to trigger a robust ...

About 30% of patients with serous endometrial cancer have tumors that express FRα, the target of mirvetuximab soravtansine, an antibody-drug conjugate (ADC). ADCs work by pairing a potent anti-cancer ...